Press Releases for OMRI

Press Releases
Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.
Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
Law Offices of Brian M. Felgoise, P.C. Announces Class Action Lawsuit on Behalf of Shareholders of Omrix Biopharmaceuticals, Inc. -- OMRI
Johnson & Johnson Begins Tender Offer to Acquire Omrix
Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
Omrix Biopharmaceuticals to Webcast Presentation at Credit Suisse Annual Healthcare Conference
Omrix Biopharmaceuticals Announces Third Quarter 2008 Financial Results
Omrix Biopharmaceuticals to Webcast Presentation at Rodman & Renshaw Annual Healthcare Conference
Omrix Biopharmaceuticals Reschedules its Third Quarter 2008 Financial Results and Conference Call to an Earlier Time on November 6, 2008
Zacks Releases New Stock Picks From +21.7% Momentum Strategy: Omrix Biopharmaceuticals, Spartan Motors, Indiana Community Bancorp, Interactive Brokers Group and DXP Enterprises
Omrix Biopharmaceuticals Announces Patient Enrollment Will Resume In Fibrin Pad U.S. Phase II Clinical Trial In Mild to Moderate Bleeding
Omrix Biopharmaceuticals Announces Third Quarter 2008 Financial Results Date and Conference Call
Omrix Biopharmaceuticals Provides Preliminary Third Quarter 2008 Results and Increases 2008 Product Sales Guidance
Omrix Biopharmaceuticals Receives Approval from European Medicines Agency for Evicel Liquid Fibrin Sealant (Human)
Omrix Biopharmaceuticals Provides Update On Fibrin Pad U.S. Phase II Clinical Trial In Mild to Moderate Bleeding
Omrix Biopharmaceuticals Announces Interim Analysis Indicating Superiority of Fibrin Pad Versus SURGICEL in Mild to Moderate Bleeding In U.S. Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials
Omrix Biopharmaceuticals Completes Enrollment of Initial 90 Patients Needed to Conduct Interim Analysis in Fibrin Pad U.S. Phase II Clinical Trial
Omrix Biopharmaceuticals to Webcast Presentation at UBS Global Life Sciences Conference
Omrix Biopharmaceuticals Announces Second Quarter 2008 Financial Results
OMRIX Biopharmaceuticals Appoints Asaf Alperovitz as Chief Financial Officer
Omrix Biopharmaceuticals Receives Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Evicel(TM) Liquid Fibrin Sealant (Human)
Omrix Biopharmaceuticals Announces Second Quarter 2008 Financial Results Date and Conference Call
Omrix Biopharmaceuticals Initiates Phase II Clinical Trial in Israel for Fibrin Pad Product Candidate
Omrix Biopharmaceuticals Announces Larry Ellberger's Appointment as Chairman of the Board and the Election of Pamela McNamara as a New Director - May 27 2008 12:55AM
Omrix Biopharmaceuticals Announces First Quarter 2008 Financial Results - Jun 2 2008 12:51AM
Omrix Biopharmaceuticals Announces First Quarter 2008 Financial Results Date and Conference Call